Mylan rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company.» Read More
ALLEGAN, Mich.-- Perrigo Co., which makes store-brand over-the-counter drugs and infant formulas, said Wednesday that it received approval from the U.S. Food and Drug Administration to market an over-the-counter nicotine product similar to Nicorette mini lozenges.
*Receives FDA approval to market mini nicotine lozenges.
You’ve heard about all those big stocks that you should buy, but the pros say there are plenty of mid-size names that belong on your radar too.
Perrigo CEO Joseph Papa appeared on Wednesday's "Mad Money."
Perrigo CEO, Joseph Papa discusses his company's 11% Q2 profit rise, and its outlook on growth, with Mad Money's Jim Cramer.
A lot of people aren’t doing their homework and those people are losing money.
When it comes to combating financial markets that all seem to move in unison, the options are getting so limited that some are questioning whether stock picking is a dying art.
Cramer and his researcher, Nicole Urken, discuss why homework—particularly during earnings season—remains important to recognizing the stock winners of the coming years.
Joseph Papa sits down with Cramer and explains why things are looking good for the private label drug maker.
Mad Money host Jim Cramer takes a look at Perrigo, which develops, manufactures and distributes private label goods to retailers. Joseph Papa, chairman, president & CEO of Perrigo, weighs in. "Our products are popular in both bull and bear markets," he says.
The “Mad Money” host explains why Europe’s problems trump good news out of the US.
There's a lot going on in this volatile market, but Cramer thinks it's important to monitor the following things in particular.
Here's a day-by-day look at the earnings reports, economic data and political events Cramer plans to monitor.
"It was the best of times, it was the worst of times." That's probably what people will say when they look back on this "increasingly Dickensian era," Cramer said.
As the U.S.'s middle class withers away, the traditional defensive plays aren't working anymore.
The "Mad Money" host reveals his "Game Plan."
Investors dumping these kinds of companies might regret it, the "Mad Money" host said.
Cramer explains when it's never a good idea to abandon turbo-charged growth stocks.
How can you tell when it's time to abandon a high-flyer? Money managers love to bet against growth stocks whenever an analyst downgrades them to a sell. Never buy a stock because it looks cheap. And don't bet against something just because it looks too rich, says Cramer.
The Mad Money host sees opportunities, though, in upcoming IPOs and recent M&A activity, though.